• Mashup Score: 1

    AmsterdamMulti-modality imaging-assisted diagnosis and follow up in patients with myocardial storage diseases Sponsored by Philips Tutorial 5 AmsterdamLearning by doing. Assessing left and right ventricle function using strain Sponsored by GE Healthcare Tutorial 7 AmsterdamHeart failure device therapies: state of the art Sponsored by Abbott Tutorial 11 Amsterdam OnlineHow to deal…

    Tweet Tweets with this article
    • During the 2023 #ESCCongress, learn more about the impact and management of #IronDeficiency in patients with #HeartDisease https://t.co/stwTG8a1br @BiykemB https://t.co/6OI64XDYwd

  • Mashup Score: 1

    Data Privacy: During the congress your online activity is tracked and collected by the ESC. We use this to award your CME credits; for reporting and statistical purposes; and to provide you with the best experience. Please note your details will be shared with the sponsor of any Industry Session, Tutorial or Exhibition you choose to view. More information is available in the ESC Congress 2023…

    Tweet Tweets with this article
    • During the 2023 #ESCCongress, learn more about the impact and management of #IronDeficiency in patients with #HeartDisease https://t.co/stwTG8a1br @BiykemB https://t.co/tC2lKpDdM7

  • Mashup Score: 3

    A new study found that, worldwide, aspirin is underused as a prevention measure in individuals with a history of cardiovascular disease (CVD). The findings were reported in JAMA. “Aspirin is an effective and low-cost option for reducing CVD events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD,” the researchers wrote. In this cross-sectional

    Tweet Tweets with this article
    • A new study found that, worldwide, aspirin is underused as a prevention measure in individuals with a history of cardiovascular disease. #CVD #heartdisease #aspirin #preventativecardiology https://t.co/tKEFFPuG90 https://t.co/QdyiIFQNTF

  • Mashup Score: 3

    Objectives To develop a tool including exercise electrocardiography (ExECG) for patient-specific clinical likelihood estimation of patients with suspected obstructive coronary artery disease (CAD). Methods An ExECG-weighted clinical likelihood (ExECG-CL) model was developed in a training cohort of patients with suspected obstructive CAD undergoing ExECG. Next, the ExECG-CL model was applied in a CAD validation cohort undergoing ExECG and clinically driven invasive coronary angiography and a prognosis validation cohort and compared with the risk factor-weighted clinical likelihood (RF-CL) model for obstructive CAD discrimination and prognostication, respectively. In the CAD validation cohort, obstructive CAD was defined as >50% diameter stenosis on invasive coronary angiography. For prognosis, the endpoint was non-fatal myocardial infarction and death. Results The training cohort consisted of 1214 patients (mean age 57 years, 57% males). In the CAD (N=408; mean age 55 years, 53% males)

    Tweet Tweets with this article
    • Exercise electrocardiography for pre-test assessment of the likelihood of coronary artery disease https://t.co/GLhMChcKfM #ECG #heartdisease #diagnosis #cardiotwitter via @Heart_BMJ

  • Mashup Score: 0

    Home > Payal Kohli > Dr. Kohli on the SELECT Trial: Semaglutide Reduces MACE in Obese Patients With Heart Disease Novo Nordisk recently announced the headline results from the SELECT cardiovascular outcomes trial, which showed that semaglutide, a GLP-1 receptor agonist, reduces major adverse cardiovascular events in overweight or obese adults with cardiovascular disease. DocWire News Medical Lead Dr. Payal Kohli talked about this landmark study and the impact of the findings on the cardiovascular community.

    Tweet Tweets with this article
    • @payalkohlimd discusses the SELECT trial, which demonstrated that #semaglutide reduces #MACE in overweight or obese adults with cardiovascular disease.https://t.co/IGB2vqMWnt #CVD #heartdisease #obesity https://t.co/SgIgm6mR99